scholarly journals Effect of High-dose Intravenous Vitamin C on Prognosis in Patients with SARS-CoV-2 Pneumonia

2021 ◽  
Author(s):  
Kavurgacı Suna ◽  
Şener Uzel Melahat ◽  
Yıldız Murat ◽  
Öztürk Ergür Figen ◽  
Öztürk Ayperi
Keyword(s):  
Vitamin C ◽  
High Dose ◽  
Intravenous Vitamin

scholarly journals High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report

2016 ◽  
Vol 17 ◽  
pp. 774-781 ◽  
Author(s):  
Nina Mikirova ◽  
Ronald Hunnunghake ◽  
Ruth C. Scimeca ◽  
Charles Chinshaw ◽  
Faryal Ali ◽  
...  
Keyword(s):  
Case Report ◽  
Vitamin C ◽  
Neurofibromatosis Type 1 ◽  
Neurofibromatosis Type ◽  
Optic Pathway Glioma ◽  
High Dose ◽  
Optic Pathway ◽  
Intravenous Vitamin

scholarly journals High-dose vitamin C infusion for the treatment of critically ill COVID-19

2020 ◽  
Author(s):  
Jing Zhang ◽  
Xin Rao ◽  
Yiming Li ◽  
Yuan Zhu ◽  
Fang Liu ◽  
...  
Keyword(s):  
Placebo Group ◽  
Vitamin C ◽  
Critically Ill ◽  
Day Treatment ◽  
Invasive Mechanical Ventilation ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
C 50 ◽  
Intravenous Vitamin ◽  
High Dose Vitamin

Abstract BackgroundNo specific medication has been proven effective for the treatment of patients with severe coronavirus disease 2019 (COVID-19). Here, we tested whether high-dose vitamin C infusion was effective for severe COVID-19.MethodsThis randomized, controlled clinical trial was performed at 3 hospitals in Hubei, China. Patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the ICU were randomly assigned in as 1:1 ratio to either the high-dose intravenous vitamin C (HDIVC) or the placebo. HDIVC group received 12 g of vitamin C/50 ml every 12 hours for 7 days at a rate of 12 ml/hour, and the placebo group received bacteriostatic water for injection in the same way. The primary outcome was invasive mechanical ventilation-free days in 28 days(IMVFD28). Secondary outcomes were 28-day mortality, organ failure, and inflammation progression.ResultsFifty-four critical COVID-19 patients were ultimately recruited. There was no difference in IMVFD28 between two groups. During the 7-day treatment period, patients in the HDIVC group had a steady rise in the PaO2/FiO2 (day 7: 229 vs. 151 mmHg, 95% CI 33 to 122, P = 0.01). Patients with SOFA scores ≥ 3 in the HDIVC group exhibited a significant reduction in 28-day mortality (P = 0.05) in univariate survival analysis. IL-6 in the VC group was lower than that in the placebo group (19.42 vs. 158.00; 95% CI -301.72 to -29.79; P = 0.04) on day 7.ConclusionThe addition of HDIVC may provide a protective clinical effect without any adverse events in critically ill patients with COVID-19.Clinicaltrial.gov identifer: NCT04264533

scholarly journals Early high-dose vitamin C in post-cardiac arrest syndrome (VITaCCA): study protocol for a randomized, double-blind, multi-center, placebo-controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Sander Rozemeijer ◽  
Harm-Jan de Grooth ◽  
Paul W. G. Elbers ◽  
Armand R. J. Girbes ◽  
Corstiaan A. den Uil ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Vitamin C ◽  
Organ Failure ◽  
Controlled Trial ◽  
Lung Injury Score ◽  
High Dose ◽  
Double Blind ◽  
Link Type ◽  
Search Trial ◽  
Intravenous Vitamin

Abstract Background High-dose intravenous vitamin C directly scavenges and decreases the production of harmful reactive oxygen species (ROS) generated during ischemia/reperfusion after a cardiac arrest. The aim of this study is to investigate whether short-term treatment with a supplementary or very high-dose intravenous vitamin C reduces organ failure in post-cardiac arrest patients. Methods This is a double-blind, multi-center, randomized placebo-controlled trial conducted in 7 intensive care units (ICUs) in The Netherlands. A total of 270 patients with cardiac arrest and return of spontaneous circulation will be randomly assigned to three groups of 90 patients (1:1:1 ratio, stratified by site and age). Patients will intravenously receive a placebo, a supplementation dose of 3 g of vitamin C or a pharmacological dose of 10 g of vitamin C per day for 96 h. The primary endpoint is organ failure at 96 h as measured by the Resuscitation-Sequential Organ Failure Assessment (R-SOFA) score at 96 h minus the baseline score (delta R-SOFA). Secondary endpoints are a neurological outcome, mortality, length of ICU and hospital stay, myocardial injury, vasopressor support, lung injury score, ventilator-free days, renal function, ICU-acquired weakness, delirium, oxidative stress parameters, and plasma vitamin C concentrations. Discussion Vitamin C supplementation is safe and preclinical studies have shown beneficial effects of high-dose IV vitamin C in cardiac arrest models. This is the first RCT to assess the clinical effect of intravenous vitamin C on organ dysfunction in critically ill patients after cardiac arrest. Trial registration ClinicalTrials.gov NCT03509662. Registered on April 26, 2018. https://clinicaltrials.gov/ct2/show/NCT03509662European Clinical Trials Database (EudraCT): 2017-004318-25. Registered on June 8, 2018. https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004318-25/NL

scholarly journals A Pharmacokinetic Study of High‐Dose Intravenous Vitamin C in Healthy Volunteers and Oncological Patients

2021 ◽  
Vol 35 (S1) ◽  
Author(s):  
Ping Chen ◽  
Yan Ma ◽  
Gregory Reed ◽  
Yu Jiang ◽  
Mark Levine ◽  
...  
Keyword(s):  
Vitamin C ◽  
Healthy Volunteers ◽  
Pharmacokinetic Study ◽  
High Dose ◽  
Oncological Patients ◽  
Intravenous Vitamin

scholarly journals Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study

2018 ◽  
Vol 46 (9) ◽  
pp. 3640-3655 ◽  
Author(s):  
Claudia Vollbracht ◽  
Martin Raithel ◽  
Bianka Krick ◽  
Karin Kraft ◽  
Alexander F. Hagel
Keyword(s):  
Vitamin C ◽  
Observational Study ◽  
Allergic Diseases ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
Definitive Evidence ◽  
Key Factor ◽  
Allergy Treatment ◽  
Intravenous Vitamin ◽  
Disease Specific

Objective Oxidative stress appears to be a key factor in the pathogenesis of allergic diseases and a potential therapeutic target in allergy treatment. Allergic diseases are reportedly associated with reduced plasma levels of ascorbate, which is a key physiological antioxidant. Ascorbate prevents excessive inflammation without reducing the defensive capacity of the immune system. Methods An interim analysis of a multicenter, prospective, observational study was conducted to investigate the change in disease-specific and nonspecific symptoms (fatigue, sleep disorders, depression, and lack of mental concentration) during adjuvant treatment with intravenous vitamin C (Pascorbin®; Pascoe, Giessen, Germany) in 71 patients with allergy-related respiratory or cutaneous indications. Results Between the start and end of treatment, the mean sum score of three disease-specific symptoms decreased significantly by 4.71 points and that of four nonspecific symptoms decreased significantly by 4.84 points. More than 50% of patients took no other allergy-related medication besides vitamin C. Conclusions Our observations suggest that treatment with intravenous high-dose vitamin C reduces allergy-related symptoms. Our observations form a basis for planning a randomized controlled clinical trial to obtain more definitive evidence of the clinical relevance of our findings. We also obtained evidence of ascorbate deficiency in allergy-related diseases. Trial registration: Clinical Trials NCT02422901.

High-dose intravenous vitamin C improves quality of life in cancer patients

2012 ◽  
Vol 1 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Hidenori Takahashi ◽  
Haruyoshi Mizuno ◽  
Atsuo Yanagisawa
Keyword(s):  
Quality Of Life ◽  
Vitamin C ◽  
Cancer Patients ◽  
High Dose ◽  
Intravenous Vitamin

scholarly journals Effect of high-dose intravenous vitamin C on inflammation in cancer patients

2012 ◽  
Vol 10 (1) ◽  
Author(s):  
Nina Mikirova ◽  
Joseph Casciari ◽  
Andrea Rogers ◽  
Paul Taylor
Keyword(s):  
Vitamin C ◽  
Cancer Patients ◽  
High Dose ◽  
Intravenous Vitamin

scholarly journals High-doses vitamin C improves cardiac injury through attenuating hyperinflammation in COVID-19

2021 ◽  
Author(s):  
Guozhi Xia ◽  
Di Fan ◽  
Chaoran Ma ◽  
Yanru He ◽  
Yaohu Zhu ◽  
...  
Keyword(s):  
Vitamin C ◽  
Critically Ill ◽  
Electronic Medical Records ◽  
Medical Records ◽  
Inflammatory Markers ◽  
Troponin I ◽  
Cardiac Injury ◽  
High Dose ◽  
High Doses ◽  
Intravenous Vitamin

Background: Cardiac injury is common and associated with worse clinical outcomes in COVID-19. Data are lacking whether high-dose intravenous vitamin C (HIVC) could help to improve cardiac injury in the pandemic. Methods: The study included severe and critically ill COVID-19 with cardiac injury. Troponin I and inflammatory markers were collected at admission and 14 days after treatment with HIVC along with symptomatic supportive treatment from the electronic medical records. Results: The patients (n = 113) were categorized into the improved cardiac injury (ICI) group (n = 70) and the non-improved cardiac injury (NICI) group (n = 43). Overall, 51 (45.1%) patients were administrated with HIVC, the percentages of patients with HIVC were higher in the ICI group than those in the NICI group. Logistic regression analysis revealed that HIVC was independently associated with improved cardiac injury. Further analysis showed that inflammatory markers levels significantly decreased at 14 days after treatment with HIVC compared to those without HIVC. Meanwhile, similar results were also observed regarding changes in inflammatory markers levels from baseline to 14 days after treatment with HIVC. Conclusions: HIVC can improve cardiac injury through attenuating hyperinflammation in severe and critically ill patients with COVID-19.

Sign in / Sign up

Export Citation Format

Share Document